191 related articles for article (PubMed ID: 38334171)
1. GBP2 enhances paclitaxel sensitivity in triple‑negative breast cancer by promoting autophagy in combination with ATG2 and inhibiting the PI3K/AKT/mTOR pathway.
Zhang W; Tang X; Peng Y; Xu Y; Liu L; Liu S
Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38334171
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models.
Cocco S; Leone A; Roca MS; Lombardi R; Piezzo M; Caputo R; Ciardiello C; Costantini S; Bruzzese F; Sisalli MJ; Budillon A; De Laurentiis M
J Transl Med; 2022 Jun; 20(1):290. PubMed ID: 35761360
[TBL] [Abstract][Full Text] [Related]
3. Hsa_circ_0000199 facilitates chemo-tolerance of triple-negative breast cancer by interfering with miR-206/613-led PI3K/Akt/mTOR signaling.
Li H; Xu W; Xia Z; Liu W; Pan G; Ding J; Li J; Wang J; Xie X; Jiang D
Aging (Albany NY); 2021 Jan; 13(3):4522-4551. PubMed ID: 33495420
[TBL] [Abstract][Full Text] [Related]
4. The PI3K/mTOR dual inhibitor NVP-BEZ235 stimulates mutant p53 degradation to exert anti-tumor effects on triple-negative breast cancer cells.
Cai J; Xia J; Zou J; Wang Q; Ma Q; Sun R; Liao H; Xu L; Wang D; Guo X
FEBS Open Bio; 2020 Apr; 10(4):535-545. PubMed ID: 32027103
[TBL] [Abstract][Full Text] [Related]
5. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
Costa RLB; Han HS; Gradishar WJ
Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
[TBL] [Abstract][Full Text] [Related]
6. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of miR‑214 attenuates the migration and invasion of triple‑negative breast cancer cells.
Zhang Y; Zhao Z; Li S; Dong L; Li Y; Mao Y; Liang Y; Tao Y; Ma J
Mol Med Rep; 2019 May; 19(5):4035-4042. PubMed ID: 30942417
[TBL] [Abstract][Full Text] [Related]
8. Rhizoma Amorphophalli inhibits TNBC cell proliferation, migration, invasion and metastasis through the PI3K/Akt/mTOR pathway.
Wu C; Qiu S; Liu P; Ge Y; Gao X
J Ethnopharmacol; 2018 Jan; 211():89-100. PubMed ID: 28962890
[TBL] [Abstract][Full Text] [Related]
9. Protective effect of hsa-miR-570-3p targeting CD274 on triple negative breast cancer by blocking PI3K/AKT/mTOR signaling pathway.
Wang LL; Huang WW; Huang J; Huang RF; Li NN; Hong Y; Chen ML; Wu F; Liu J
Kaohsiung J Med Sci; 2020 Aug; 36(8):581-591. PubMed ID: 32311203
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA‑22 mediates the cisplatin resistance of osteosarcoma cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway.
Meng CY; Zhao ZQ; Bai R; Zhao W; Wang YX; Xue HQ; Sun L; Sun C; Feng W; Guo SB
Oncol Rep; 2020 Apr; 43(4):1169-1186. PubMed ID: 32323781
[TBL] [Abstract][Full Text] [Related]
11. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
Chen D; Lin X; Zhang C; Liu Z; Chen Z; Li Z; Wang J; Li B; Hu Y; Dong B; Shen L; Ji J; Gao J; Zhang X
Cell Death Dis; 2018 Jan; 9(2):123. PubMed ID: 29374144
[TBL] [Abstract][Full Text] [Related]
12. Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer.
Wen W; Marcinkowski E; Luyimbazi D; Luu T; Xing Q; Yan J; Wang Y; Wu J; Guo Y; Tully D; Han ES; Yost SE; Yuan Y; Yim JH
Cells; 2019 Aug; 8(9):. PubMed ID: 31480338
[TBL] [Abstract][Full Text] [Related]
13. CircWAC induces chemotherapeutic resistance in triple-negative breast cancer by targeting miR-142, upregulating WWP1 and activating the PI3K/AKT pathway.
Wang L; Zhou Y; Jiang L; Lu L; Dai T; Li A; Chen Y; Zhang L
Mol Cancer; 2021 Mar; 20(1):43. PubMed ID: 33648498
[TBL] [Abstract][Full Text] [Related]
14. Silence of α1-Antitrypsin Inhibits Migration and Proliferation of Triple Negative Breast Cancer Cells.
Zhao Z; Ma J; Mao Y; Dong L; Li S; Zhang Y
Med Sci Monit; 2018 Sep; 24():6851-6860. PubMed ID: 30260937
[TBL] [Abstract][Full Text] [Related]
15. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
De P; Sun Y; Carlson JH; Friedman LS; Leyland-Jones BR; Dey N
Neoplasia; 2014 Jan; 16(1):43-72. PubMed ID: 24563619
[TBL] [Abstract][Full Text] [Related]
16. HER3/Akt/mTOR pathway is a key therapeutic target for the reduction of triple‑negative breast cancer metastasis via the inhibition of CXCR4 expression.
Takeda T; Tsubaki M; Genno S; Tokunaga K; Tanaka R; Nishida S
Int J Mol Med; 2023 Sep; 52(3):. PubMed ID: 37477145
[TBL] [Abstract][Full Text] [Related]
17. The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor.
Tzeng HE; Yang L; Chen K; Wang Y; Liu YR; Pan SL; Gaur S; Hu S; Yen Y
Oncotarget; 2015 May; 6(13):11061-73. PubMed ID: 25857298
[TBL] [Abstract][Full Text] [Related]
18. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer.
Song H; Wu T; Xie D; Li D; Hua K; Hu J; Fang L
Cell Physiol Biochem; 2018; 48(5):1968-1982. PubMed ID: 30092563
[TBL] [Abstract][Full Text] [Related]
19. Salidroside induces apoptosis and protective autophagy in human gastric cancer AGS cells through the PI3K/Akt/mTOR pathway.
Rong L; Li Z; Leng X; Li H; Ma Y; Chen Y; Song F
Biomed Pharmacother; 2020 Feb; 122():109726. PubMed ID: 31918283
[TBL] [Abstract][Full Text] [Related]
20. miR-142-3p improves paclitaxel sensitivity in resistant breast cancer by inhibiting autophagy through the GNB2-AKT-mTOR Pathway.
Shi Y; Wang J; Tao S; Zhang S; Mao L; Shi X; Wang W; Cheng C; Shi Y; Yang Q
Cell Signal; 2023 Mar; 103():110566. PubMed ID: 36539001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]